title: Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis.
abstract: OBJECTIVE
  Treatment of refractory Hodgkin disease deserves specific considerations. Recently, alemtuzumab-BEAM has been introduced in allogeneic hematopoietic stem cell transplantation (HSCT) in these patients.
  
  
  METHODS
  We retrospectively analyzed the outcome of 20 patients with relapsed/refractory Hodgkin's lymphoma (HL) who received allogeneic HSCT following conditioning therapy with alemtuzumab-BEAM.
  
  
  RESULTS
  Treatment-related toxicity was tolerable. Half of the patients (50 %) had infections. Of these, 50 % were found to have pneumonia or catheter-related infections. In 20 %, an oral mucositis was observed. Acute graft-versus-host disease (GvHD) (≥grade 2) was seen in three patients. Complete remission (CR) could be achieved in 17 patients (85 %), 2 patients had persistent Hodgkin disease, and 1 patient died from infection prior to CR evaluation. Median progression-free survival and overall survival were 17.9 and 67.5 months, respectively. From the 17 CR patients, 8 had a relapse after a median of 10 months. Notably, of the eight patients relapsing after HSCT, all patients received another salvage treatment and four patients are still alive, whereas the other four patients died due to further progress. Six out of the remaining nine patients are still in CR, whereas the other three died from chronic GvHD and multi-organ failure. Overall, seven patients experienced chronic GvHD.
  
  
  CONCLUSIONS
  In summary, alemtuzumab-BEAM is a well-tolerated conditioning therapy for allogeneic HSCT with high response rates in refractory HL.
authors.affiliation: Bone Marrow Transplant Unit, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
authors.forename: W
authors.initials: W
authors.lastname: Rabitsch
authors.affiliation: Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.
authors.forename: M
authors.initials: M
authors.lastname: Bojic
authors.affiliation: Bone Marrow Transplant Unit, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
authors.forename: P
authors.initials: P
authors.lastname: Wohlfarth
authors.affiliation: Bone Marrow Transplant Unit, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
authors.forename: M
authors.initials: M
authors.lastname: Leiner
authors.affiliation: Bone Marrow Transplant Unit, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
authors.forename: C
authors.initials: C
authors.lastname: Schörgenhofer
authors.affiliation: Bone Marrow Transplant Unit, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
authors.forename: P
authors.initials: P
authors.lastname: Kalhs
authors.affiliation: Bone Marrow Transplant Unit, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
authors.forename: A
authors.initials: A
authors.lastname: Schulenburg
authors.affiliation: Department of Medicine I, Clinical Division of Hematology, Medical University of Vienna, Vienna, Austria.
authors.forename: C
authors.initials: C
authors.lastname: Sillaber
authors.affiliation: Bone Marrow Transplant Unit, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
authors.forename: M
authors.initials: M
authors.lastname: Mitterbauer
authors.affiliation: Department of Medicine I, Clinical Division of Hematology, Medical University of Vienna, Vienna, Austria.
authors.forename: W R
authors.initials: WR
authors.lastname: Sperr
authors.affiliation: Department of Medicine I, Clinical Division of Hematology, Medical University of Vienna, Vienna, Austria.
authors.forename: U
authors.initials: U
authors.lastname: Jäger
authors.affiliation: Department of Medicine I, Clinical Division of Hematology, Medical University of Vienna, Vienna, Austria.
authors.forename: K
authors.initials: K
authors.lastname: Skrabs
authors.affiliation: Division of Hematology, Medical University of Graz, Graz, Austria.
authors.forename: H
authors.initials: H
authors.lastname: Greinix
authors.affiliation: Department of Medicine I, Intensive Care Unit 13i2, Medical University of Vienna, Vienna, Austria.
authors.forename: A
authors.initials: A
authors.lastname: Hermann
authors.affiliation: Bone Marrow Transplant Unit, Department of Medicine I, Medical University of Vienna, Vienna, Austria. wolfgang.lamm@meduniwien.ac.at.|Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. wolfgang.lamm@meduniwien.ac.at.
authors.forename: W
authors.initials: W
authors.lastname: Lamm
mesh_terms: D000328:Adult; D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002330:Carmustine / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006086:Graft vs Host Disease; D006689:Hodgkin Disease / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D012008:Recurrence; D019172:Transplantation Conditioning; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003561:Cytarabine; D000074323:Alemtuzumab; D005047:Etoposide; D008558:Melphalan; D002330:Carmustine
keywords: Alemtuzumab-BEAM; Allogeneic HSCT; Hodgkin lymphoma